Safety and efficacy of gliadel wafers for newly diagnosed and recurrent glioblastoma

Pasquale De Bonis, Carmelo Anile, Angelo Pompucci, Alba Fiorentino, Mario Balducci, Silvia Chiesa, Giulio Maira, Annunziato Mangiola

Research output: Contribution to journalArticle

Abstract

Background Combining Gliadel wafers and radiochemotherapy with TMZ may carry the risk of increased adverse events (AE). We analyzed the efficacy and safety in patients with glioblastoma who underwent multimodal treatment with implantation of Gliadel wafers. Methods One hundred sixty-five consecutive patients with newly diagnosed (77 patients) or recurrent (88 patients) glioblastoma were studied. Forty-seven patients underwent surgery + Gliadel. The impact of age (≥65 vs.

Original languageEnglish
Pages (from-to)1371-1378
Number of pages8
JournalActa Neurochirurgica
Volume154
Issue number8
DOIs
Publication statusPublished - Aug 2012

    Fingerprint

Keywords

  • Carmustine-wafers
  • Efficacy
  • Gliadel
  • Glioblastoma
  • Safety
  • Toxicity

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

De Bonis, P., Anile, C., Pompucci, A., Fiorentino, A., Balducci, M., Chiesa, S., Maira, G., & Mangiola, A. (2012). Safety and efficacy of gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochirurgica, 154(8), 1371-1378. https://doi.org/10.1007/s00701-012-1413-2